Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Correlation of novel ALKATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma.

Publication ,  Journal Article
Shah, KK; Neff, JL; Erickson, LA; Jackson, RA; Jenkins, SM; Mansfield, AS; Moser, JC; Harris, AL; Copland, JA; Halling, KC; Flotte, TJ
Published in: Histopathology
October 2020

AIMS: Recently, a novel isoform of anaplastic lymphoma kinase, with alternative transcription initiation (ALKATI ), has been described in melanoma and is susceptible to targeted ALK-inhibitor therapy. Clinical outcomes of patients with ALKATI mutated melanoma as well as correlation with immunohistochemical (IHC) methods have not yet been described. METHODS AND RESULTS: Clinicopathological characteristics were abstracted for 324 patients with metastatic melanoma (MM). IHC, fluorescence in-situ hybridisation and RNA-based digital molecular analysis assays were performed on archival tissue from 173 stage III and 192 stage IV tumours. ALKATI was identified in 12.7 and 4.8% stage III and IV tumours, respectively. Discrete presentations of the ALKATI are seen: isolated ALKATI (n = 20) and mixed ALKATI (combined ALKATI and ALKWT ; n = 7). Isolated ALKWT expression (n = 4) was seen with no ALK fusions. Stage III patients showed improved survival with ALKATI expression compared to those with ALKWT or no expression [5-year survival 80, 95% confidence interval (CI) = 57-100% versus 43%, 95% CI = 34-55%, P = 0.013]. Clinicopathological characteristics were not statistically significant. Strong diffuse cytoplasmic staining of ALK IHC (n = 12) has a sensitivity of 52.2%, specificity 100%, PPV of 100% and NPV of 92.5% of detecting isolated ALKATI . CONCLUSION: Presence of ALKATI is a good prognostic indicator in MM. ALK IHC and digital molecular analysis can be incorporated into MM evaluation to identify patients with ALKATI for targeted therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Histopathology

DOI

EISSN

1365-2559

Publication Date

October 2020

Volume

77

Issue

4

Start / End Page

601 / 610

Location

England

Related Subject Headings

  • Skin Neoplasms
  • Retrospective Studies
  • Protein Isoforms
  • Pathology
  • Middle Aged
  • Melanoma, Cutaneous Malignant
  • Melanoma
  • Male
  • Immunohistochemistry
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shah, K. K., Neff, J. L., Erickson, L. A., Jackson, R. A., Jenkins, S. M., Mansfield, A. S., … Flotte, T. J. (2020). Correlation of novel ALKATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. Histopathology, 77(4), 601–610. https://doi.org/10.1111/his.14191
Shah, Kabeer K., Jadee L. Neff, Lori A. Erickson, Rory A. Jackson, Sarah M. Jenkins, Aaron S. Mansfield, Justin C. Moser, et al. “Correlation of novel ALKATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma.Histopathology 77, no. 4 (October 2020): 601–10. https://doi.org/10.1111/his.14191.
Shah KK, Neff JL, Erickson LA, Jackson RA, Jenkins SM, Mansfield AS, et al. Correlation of novel ALKATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. Histopathology. 2020 Oct;77(4):601–10.
Shah, Kabeer K., et al. “Correlation of novel ALKATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma.Histopathology, vol. 77, no. 4, Oct. 2020, pp. 601–10. Pubmed, doi:10.1111/his.14191.
Shah KK, Neff JL, Erickson LA, Jackson RA, Jenkins SM, Mansfield AS, Moser JC, Harris AL, Copland JA, Halling KC, Flotte TJ. Correlation of novel ALKATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. Histopathology. 2020 Oct;77(4):601–610.
Journal cover image

Published In

Histopathology

DOI

EISSN

1365-2559

Publication Date

October 2020

Volume

77

Issue

4

Start / End Page

601 / 610

Location

England

Related Subject Headings

  • Skin Neoplasms
  • Retrospective Studies
  • Protein Isoforms
  • Pathology
  • Middle Aged
  • Melanoma, Cutaneous Malignant
  • Melanoma
  • Male
  • Immunohistochemistry
  • Humans